Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4017 participants.

Also called NCT04564742

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,017 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04564742
  • EudraCT 2020-000664-31
Other papers using this trial's data
  • Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure NEJM evidence, 2024-02 DOI, PubMed 38320489

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04564742. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-22 (actual); primary completion 2023-07-05 (actual). Results posted on 2025-03-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
Acronym
DAPA-MI
Condition
Acute Myocardial Infarction
Condition
Heart Failure
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Uppsala University (class: other)

Record details

Record id
cardio:ct-nct04564742
Content hash
41a5ba6a54f4375210d4e8455f673a486438906eed8bfe770e0f1ab83fa81bbc